Deciphera Pharmaceuticals, Inc. (DCPH)
Stock Price:
$52.33 USD
-1.08 (-2.02%)
Updated Jul 16, 2020 1:44 PM EDT - Market open
Key Info
| Market Cap |
2.92B |
| Revenue (ttm) |
25.06M |
| Net Income (ttm) |
-217.68M |
| Shares Out |
55.86M |
| EPS (ttm) |
-4.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 16, 2020 |
| Last Price |
$52.33 |
| Previous Close |
$53.41 |
| Change ($) |
-1.08 |
| Change (%) |
-2.02% |
| Day's Open |
52.86 |
| Day's Range |
51.39 - 53.31 |
| Day's Volume |
116,011 |
| 52-Week Range |
19.88 - 71.11 |
More Stats
| Market Cap |
2.92B |
| Enterprise Value |
2.25B |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
55.86M |
| Float |
33.95M |
| EPS (basic) |
-4.56 |
| EPS (diluted) |
-4.66 |
| FCF / Share |
-3.78 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.40M |
| Short Ratio |
7.27 |
| Short % of Float |
11.25% |
| Beta |
2.17 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
116.64 |
| PB Ratio |
4.36 |
| Revenue |
25.06M |
| Operating Income |
-226.96M |
| Net Income |
-217.68M |
| Free Cash Flow |
-202.22M |
| Net Cash |
674.40M |
| Net Cash / Share |
12.07 |
| Gross Margin |
99.75% |
| Operating Margin |
-905.61% |
| Profit Margin |
-868.60% |
| FCF Margin |
-806.89% |
| ROA |
-28.00% |
| ROE |
-47.72% |
| ROIC |
-56.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (12)
| Buy |
10 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$72.50*
(38.54% upside)
Low
55.0
Current: 52.33
High
91.0
Target: 72.50
*Average 12-month price target from 12 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 25.00 | - | - | - | - |
| Gross Profit | 25.00 | - | - | - | - |
| Operating Income | -201 | -104 | -50.94 | -25.84 | -17.61 |
| Net Income | -192 | -99.85 | -50.28 | -25.94 | -19.82 |
| Shares Outstanding | 42.87 | 35.39 | 16.79 | 11.63 | 4.25 |
| Earnings Per Share | -4.48 | -2.82 | -2.99 | -2.23 | -4.67 |
| Operating Cash Flow | -149 | -86.78 | -36.70 | -23.09 | -13.27 |
| Capital Expenditures | -4.94 | -1.13 | -0.41 | -0.22 | -0.14 |
| Free Cash Flow | -154 | -87.91 | -37.11 | -23.31 | -13.41 |
| Cash & Equivalents | 580 | 294 | 197 | 57.46 | 25.78 |
| Total Debt | 17.65 | 13.18 | 1.48 | 1.67 | 1.87 |
| Net Cash / Debt | 562 | 281 | 195 | 55.79 | 23.91 |
| Assets | 622 | 316 | 199 | 58.95 | 26.79 |
| Liabilities | 75.94 | 35.58 | 15.12 | 6.04 | 4.73 |
| Book Value | 546 | 280 | 184 | -140 | -115 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Deciphera Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
255 |
| CEO |
Steven L. Hoerter |
Stock Information
| Ticker Symbol |
DCPH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: DCPH |
| IPO Date |
September 28, 2017 |
Description
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.